64 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
13 more records may belong here and await a decision; they are not counted.
The next term ends in Apr 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Apr 2027
Next term end
18
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2036 · High confidence
Also notable
Ends Jan 2040 · High confidence
Also notable
Ends Oct 2036 · High confidence
Modulators of SESTRIN-GATOR2 Interaction and Uses Thereof
US 11,325,924
Cited by 13 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Polymorphic Compounds and Uses Thereof
US 11,345,654
Cited by 13 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2040.
Modulators of SESTRIN-GATOR2 Interaction and Uses Thereof
US 10,912,750
Cited by 18 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 11 to 20, 2026 · next Dec 11
- 1 fee due Jan 11, 2027The maintenance fee for Polymorphic Compounds and Uses Thereof (US 11,697,633) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 1 fee due Feb 15, 2027The maintenance fee for METHODS OF TREATMENT USING AN mTORC1 MODULATOR (US 11,723,890) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Modulators of SESTRIN-GATOR2 Interaction and Uses Thereof (US 10,414,782) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Method of Treatment of CNS Disorders (US 11,911,368) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Derivatives of Substituted Morpholines and Uses Thereof (US 11,919,889) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for Process of Making Derivatives of Substituted Morpholines (US 11,964,951) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
What they patent
The 5 largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Modified-Release Preparations Containing Oxcarbazepine and Derivatives Thereof | 10 in force | to Apr 2027 |
| Sustained-Release Formulations of Topiramate | 7 in force | to Apr 2028 |
| Methods of Producing Molindone and Its Salts | 6 in force | to Apr 2033 |
| Modulators of SESTRIN-GATOR2 Interaction and Uses Thereof | 5 in force | to Mar 2037 |
| Formulations of Viloxazine | 4 in force | to Apr 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,154,965 | Osmotic Drug Delivery System In force · Medium confidence | In force | Medium confidence | |
| US 7,722,898 | Modified-Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · High confidence | In force | High confidence | |
| US 8,821,930 | Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,119,791 | Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,119,792 | Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,351,975 | Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,370,525 | Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,855,278 | Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,220,042 | Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,166,960 | Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 64: 2 patents in force now held by others · 25 patents ended · 18 applications pending · 51 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.